Compare Amylx Pharmaceuticals Inc (AMLX) vs Advanced Drainage Systems Inc (WMS) Price & Performance

AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.

The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.

Advanced Drainage Systems (WMS) trades at $150.47, up 1.77% today, with a bullish technical signal and strong fundamental profitability. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $1.07 exceeding the $0.936 estimate. The company maintains robust margins, including a 38.27% gross profit margin and 13.98% net income margin, while cash flow trends indicate solid operational performance despite a net outflow in 2025.

The outlook is positive with a consensus price target of $183.33, suggesting 22% upside, supported by analyst buy ratings. Risks include competitive pressures and a recent Zacks Strong Sell rating, but strong ROE of 24.02% and debt-to-asset improvement to 34.34% in 2025 highlight financial health. Investors should weigh growth potential against market volatility and execution risks.